2-halo-5-alkynyl-pyridyl nicotinic ligands
Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.
1. A compound represented by the formula:
or a pharmaceutically acceptable salt thereof,
wherein, independently for each occurrence,
X is F, or Cl;
R 2 is H;
R 3 is
wherein R 10 is selected from the group consisting of H, hydroxy, halogen, and substituted or unsubstituted alkyl, aryl, and aralkyl;
wherein each substituent is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, amino, aryl, aralkyl, nitro, haloalkyl, heterocyclyl, halogen, and hydroxy; and
A is
wherein,
m is 0, 1, 2, 3, 4, or
n is 1, 2, or 3;
R 11 is H, alkyl, or alkenyl; and
R 12 is alkyl, alkoxy, alkoxyalkyl, cyano, halogen, hydroxy, hydroxyalkyl, haloalkyl, —O—C(O)-alkyl, or —O-methanesulfonyl;
wherein the absolute stereochemistry at a stereogenic center may be R or S or a mixture thereof; and the stereochemistry of a double bond may be E or Z or a mixture thereof.
2. The compound of claim 1 , wherein X is F.
3. The compound of claim 1 , wherein R 3 is selected from the group consisting of
4. The compound of claim 1 , wherein R 11 is H; and m is 0.
5. The compound of claim 1 , wherein n is 1.
6. The compound of claim 1 , wherein R 11 is H; m is 0; and n is 1.
7. The compound of claim 1 , wherein X is F; R 2 is H; and R 3 is selected from the group consisting of
8. The compound of claim 7 , wherein R 11 is H; m is 0; and n is 1.
9. The compound of claim 1 , wherein the compound has the structure:
10. A pharmaceutical composition, comprising a compound of claim 1 ; and a pharmaceutically acceptable excipient.
11. A method of modulating a nicotinic acetylcholine (Ach) receptor, comprising administering to a mammal in need thereof an effective amount of a compound of claim 1 .